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Abstract
Chromosomal region 1p22 is deleted in ≥20% of multiple myeloma (MM) patients, suggesting the 
presence of an unidentified tumor suppressor. Using high-resolution genomic profiling, we delimit 
a 58 kb minimal deleted region (MDR) on 1p22.1 encompassing two genes: ectopic viral 
integration site 5 (EVI5) and ribosomal protein L5 (RPL5). Low mRNA expression of EVI5 and 
RPL5 was associated with worse survival in diagnostic cases. Patients with 1p22 deletion had 
lower mRNA expression of EVI5 and RPL5, however, 1p22 deletion status is a bad predictor of 
RPL5 expression in some cases, suggesting that other mechanisms downregulate RPL5 
expression. Interestingly, RPL5 but not EVI5 mRNA levels were significantly lower in relapsed 
patients responding to bortezomib and; both in newly diagnosed and relapsed patients, bortezomib 
treatment could overcome their bad prognosis by raising their progression-free survival to equal 
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that of patients with high RPL5 expression. In conclusion, our genetic data restrict the MDR on 
1p22 to EVI5 and RPL5 and although the role of these genes in promoting MM progression 
remains to be determined, we identify RPL5 mRNA expression as a biomarker for initial response 
to bortezomib in relapsed patients and subsequent survival benefit after long-term treatment in 
newly diagnosed and relapsed patients.
Introduction
Multiple myeloma (MM) accounts for up to 10% of all hematologic malignancies. Patient 
outcome has improved significantly in the last decade, partially due to the introduction of 
novel agents, such as immunomodulatory drugs (IMiDs) as well as the proteasome inhibitors 
(bortezomib and second generation agents carfilzomib and ixazomib). Nevertheless, not all 
patients respond to these new drugs, and factors determining response are still poorly 
understood.1,2 In the light of high costs and higher occurrence of severe side-effects such as 
peripheral neuropathy associated with bortezomib treatment1,3, future efforts should be 
directed to developing biomarkers that can identify patients that will benefit from a 
particular drug or drug scheme.
MM, like other cancers, is caused by stepwise accumulation of genetic abnormalities. 
Chromosomal translocations involving the immunoglobulin heavy (IgH) locus causing 
overexpression of targeted oncogenes are primary events. The most prevalent of these 
translocations are t(11;14)(q13;q32) and t(4;14)(p16;q32), each present in 15% of cases. In 
the absence of IgH translocations, the disease is usually characterized by hyperdiploidy, 
specifically trisomy of odd chromosomes. Secondary hits then cause progression from 
asymptomatic monoclonal gammopathy of undetermined significance (MGUS), to 
smoldering myeloma, and finally to symptomatic myeloma with organ damage and bone 
lesions. Secondary events consist of mutations, chromosomal translocations and/or copy 
number changes. The mutational spectrum of MM has recently been characterized using 
genome wide next generation sequencing, which has revealed a heterogeneous mutational 
landscape with few recurrently affected genes. Only three genes have been found to be 
mutated in more than 10% of patients: KRAS (22% of cases), NRAS (20%) and FAM46C 
(12%).4–7 With regard to chromosomal abnormalities, secondary hits consist of t(8;14)
(q24;q32) causing MYC activation, as well as copy number changes, with the most common 
ones being gains on 1q, 3p, 6p, 9p, 11q, 19p, 19q and 21q along with deletions of 1p, 4q, 
16q and 22q. For some of these regions, candidate oncogenes and tumor suppressors 
contributing to disease progression have been identified.3, 8–10
Among the deleted regions, 1p is one of the most prevalent with up to 30% of myeloma 
patients carrying the deletion. Four distinct minimally deleted regions (MDRs) have been 
identified on 1p (1p12, 1p21.3p22.1, 1p31.1 and 1p32.3), of which 1p21.3p22.1 is the most 
common one (15-22% of patients).11–13 This region is associated with higher incidence of 
t(4;14)(p16;q32) and deletion of 17p and 13q14, and is a negative prognostic factor for 
progression-free survival (PFS) and overall survival (OS) in newly diagnosed patients.13 
Low expression of several genes on 1p22 is part of a high risk MM gene signature.14 So far, 
however, no tumor suppressor has been identified on this cytoband. Previously, an MDR of 
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1p21.3p22.1 encompassing 35 genes was defined and MTF2 and TMED5 were proposed as 
candidate tumor suppressors in this region, as they show differential expression between 
deleted and non-deleted cases. However, no mutations were found in these genes, low MTF2 
expression does not affect PFS or OS, and the association between low TMED5 expression 
and shorter survival is only borderline significant.11,12
To uncover potentially clinically relevant tumor suppressors on 1p22, we performed an in-
depth genetic analysis of 1p22 in MM. We delineate an MDR encompassing only 2 genes 
(EVI5 and RPL5) and show for each of these genes that low expression is associated with 
lower survival in newly diagnosed but not in relapse patients. RPL5 expression is 
significantly lower in relapse patients with initial response to bortezomib and both newly 
diagnosed and relapse patients with low RPL5 expression have better PFS when bortezomib 
is included in their treatment scheme. We thus identify RPL5 expression levels as a novel 
clinical biomarker for response to bortezomib.
Materials and Methods
Patient samples
We studied 35 advanced diagnostic MM bone marrow samples available at UZ Leuven with 
at least 70% plasma cells (Supplementary Table 1). All cases were routinely characterized 
by FISH, as described previously.15 This study was approved by the ethical committee of 
the UZ Leuven. Copy number, mutation and gene expression data of the Multiple Myeloma 
Research Consortium (MMRC) (https://www.broadinstitute.org/mmgp/home) were also 
used. For survival analyses, we analyzed data from the phase III HOVON-65/ GMMG-HD4 
and APEX trials.16–18 In the phase III HOVON-65/ GMMG-HD4 trial, newly diagnosed 
MM patients were treated with an experimental PAD protocol (bortezomib, doxorubicin, 
dexamethasone with bortezomib maintenance) or a conventional VAD protocol (vincristine, 
doxorubicin, dexamethasone with thalidomide maintenance). In the APEX trial, bortezomib 
versus high-dose dexamethasone monotherapy was tested in relapsed patients. All study 
participants provided informed consent to use their data for research purposes and all studies 
were conducted according to the Declaration of Helsinki.
High resolution copy number arrays
UZ Leuven cases were analyzed on Cytoscan HD arrays (Affymetrix). Data were processed 
using Chromosome Analysis Suite (ChAS) software (Affymetrix) with hg19 as reference. In 
order to call a deletion, we required at least 20 consecutive markers with a weighted log2 
ratio of -0.15 or less. Raw data is available at NCBI as GEO accession GSE73976.
Analysis of gene expression levels in patients
The 245 MMRC cases with copy number and expression data available on (https://
www.broadinstitute.org/mmgp/home) were analyzed. Patients with a log2 copy number ratio 
>-0.1 for 1p22.1 were considered non-deleted; ratios <-0.6 were considered deleted. Patients 
with values between -0.1 and -0.6 were excluded.
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Bortezomib response analysis
Gene expression array data from the APEX trial were used (GSE9782). Only the bortezomib 
arm of the trial was used in this analysis. Patients with complete remission, partial response 
or minimal response were assigned to the group of responders. Patients with no change or 
progressive disease were considered non-responders. Probe sets with differential signal 
between responders and non-responders were calculated using limma (Bioconductor).19 The 
entire list of probe sets was ranked according to log2 fold changes and used as input for 
Gene Set Enrichment Analysis (GSEA) against the MSigDB C2 KEGG and C1 positional 
gene sets.20,21 Only GSEA results with a FDR q-value <0.2 were considered.
Survival analysis
For the analysis on the phase III HOVON-65/ GMMG-HD4 trial,16 327 patients with gene 
expression array profiling were included (GEO ID: GSE19784)). For the APEX trial, 264 
patients from which gene expression array data were available were analyzed (GEO ID: 
GSE9782). On each of the trial datasets, Cox regression (including both arms of the trial) 
testing association between the indicated gene levels and survival was performed if the 
proportionality criterion was met (tested using covariate time analysis). Subsequently, 
patients were divided into groups with expression levels above the median (high expression) 
and below the median (low expression) or according to the specified threshold. Kaplan-
Meier analysis was then performed on patients with either low or high expression to test the 
prognostic value of the indicated gene expression levels on survival and to test whether these 
patients differ in the benefit they get from each of the treatments.
More details on methods are available in the supplement.
Results
Delineation of a 58 kb MDR on 1p22.1 encompassing the EVI1 and RPL5 genes
We analyzed 35 advanced MM samples on high resolution copy number arrays 
(Supplementary table 1). The 1p22 cytoband, or part of it, was deleted in 15 out of 35 cases 
(43%), confirming the high incidence of 1p22 deletions in this disease (Figure 1A; 
Supplementary table 2).11–13 Loss of 1p22 was detected in cases with hyperdiploid 
karyotype (7/15) or IGH-mediated translocation/deletion (5/15). The most frequent 
aberration associated with the 1p22 loss was del(13q14/RB1) (10/15) (Supplementary table 
1). For 2 cases with deletions in bone marrow at diagnosis, buccal swab DNA was available 
and absence of the lesion in the buccal swab was confirmed by MLPA, supporting the 
somatic nature of these lesions (Supplementary figure 1).
To determine the MDR at 1p22, the average weighted log2 array values were calculated for 
each of the genes on 1p22 in our cohort (Figure 1B, Supplementary table 3), with the genes 
with the lowest value defining the MDR. Chromosome band 1p22.1 had lower values than 
1p22.2 and 1p22.3. Of interest, patients MM05 and MM02, showed highly focal deletions of 
304 kb and 366 kb with an overlap of only 58 kb. The deletion in MM05 affected the 5’ 
parts of the EVI5 and MTF2 genes, as well as the entire RPL5 and FAM69A genes and was 
confirmed by FISH (Figure 1C-D). For patient MM02, it was clear that the entire GFI1 and 
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EVI5 genes were deleted. The centromeric border in MM02 was hard to define on the array 
and by FISH, although it seemed within RPL5 (Figure 1C-D). To better delineate this 
centromeric border, the copy number status of the different exons of RPL5 was analyzed 
using MLPA (Figure 1E). This assay revealed that the deletion breakpoint was right within 
RPL5, with exons 1-4 deleted, whereas the 3’ of the gene was unaffected. We thus 
confirmed that RPL5 was part of the MDR. In conclusion, the MDR on 1p22.1 was 
restricted to a 58 kb region in our cohort, encompassing the 5’ parts of EVI5 and RPL5. 
EVI5 is a modulator of cell cycle progression, cytokinesis, and cellular membrane traffic. 
RPL5 encodes ribosomal protein L5, one of the 81 protein components of the ribosome.
RPL5 and EVI5 are the genes on 1p22.1 with most predicted functionally impairing 
mutations
We reasoned that a relevant tumor suppressor might also be targeted by mutations. 
Therefore, integration of the copy number data with mutation data might help in pinpointing 
relevant genes. Exome-wide mutation screening in large MM cohorts has been performed.4–
7 Whereas mutations in genes on 1p22 are rare in all of these studies, RPL5 was 
significantly mutated in one study with an incidence of 2/84 (2.4%).4 We analyzed the 
mutational load of all 1p22.1 genes in the MMRC exome data of 203 patients6 and 
calculated a mutation score for each gene on 1p22.1 (with a higher score referring to more 
mutations in a gene that are likely to impair protein function) (Figure 2A, Supplementary 
tables 4-5). Whereas EPHX4, a gene outside the MDR, had a high mutation score because of 
a relatively high number of gene size corrected mutations with low predicted functional 
impact, the EVI5 and RPL5 genes had the highest mutation scores (Figure 1B, Figure 2A).
EVI5 and RPL5 mRNA levels are lower in 1p22.1 deleted cases
Next, we tested if deletion of 1p22 reduces RPL5 and/or EVI5 expression levels. No high 
quality RNA was available from our patients analyzed by copy number arrays. Therefore, we 
analyzed the association between gene expression and copy number status in the MMRC 
cohort. For both genes, expression levels were significantly lower in 1p22 deleted cases as 
compared to non-deleted cases (p<0.0001) (Figure 2B). However, for EVI5, there was less 
overlap in expression levels between 1p22 wild type and deleted cases than for RPL5, as 
reflected by a slightly larger fold change in expression for EVI5 than for RPL5 when 
comparing deleted versus non-deleted cases (0.59 versus 0.71).
Low EVI5 and RPL5 expression correlates with shorter PFS and OS in newly diagnosed 
but not in relapse cases
1p22 deletion is associated with lower PFS and OS in newly diagnosed MM.13 Since 1p22 
deletion status was not available for the trial data we had access to, we could not confirm 
this previously described correlation. We tested however if EVI5 and or RPL5 expression 
levels can mirror the bad prognosis of 1p22 deletion. Cox regression analysis on the data 
from the phase III HOVON-65/ GMMG-HD4 trial (referred to as HOVON-65 later on) on 
newly diagnosed cases demonstrated that lower RPL5 levels were associated with shorter 
PFS and OS (Table 1). In agreement with this, Kaplan-Meier analysis showed a lower 
median PFS and OS in patients with RPL5 expression below median (‘RPL5 low’) than in 
patients with RPL5 expression above median (‘RPL5 high’) (Figure 3A). However, in the 
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APEX trial on relapsed patients, no association between RPL5 levels and survival was found 
(Supplementary figure 2; Table 1). Similarly, low EVI5 expression was associated with 
worse PFS and OS in the HOVON-65 but not in the APEX trial (Figure 3B and 
Supplementary figure 2; Table 1). Optimal cutoff for RPL5 expression in relation to survival 
in the HOVON-65 trial was determined at the 22.5% lowest RPL5 expressers. Using this 
cutoff instead of median RPL5 expression gave a superior separation of patients in the 
HOVON-65 trial as well as in a validation cohort for which OS data were available in the 
R2: Genomics Analysis and Visualization Platform (Supplementary figure 3A-D). For EVI5 
expression median expression was close to the best cutoff for PFS in the HOVON-65 trial 
while for OS, the optimal cutoff was determined at the 31.5% lowest EVI5 expressers. 
Application of this cutoff in the validation cohort in R2 again confirmed the superior 
separation (Supplementary figure 3E-G).
Bortezomib responders express lower levels of RPL5 and other ribosomal protein and 
translation genes
Proteasome inhibitors are now included in most therapeutic schemes of MM patients. 
Cellular protein metabolism and homeostasis, which are probably affected by proteasome 
inhibitors, might also be altered by reduced expression levels of a ribosomal protein like 
RPL5. To investigate this potential association, data from the APEX clinical trial were 
analyzed. In this trial, relapse patients were treated with bortezomib or dexamethasone as 
single agent.17 In the bortezomib arm of the trial (n=169), RPL5 mRNA expression was 
significantly lower in the bortezomib responders than in non-responders (fold change 
responders versus non-responders: 0.68, p<0.0001) (Figure 4A). When analyzing all 
differentially expressed genes between responders and non-responders in this trial arm, 1211 
probe sets were significant (adjusted p-value < 0.2). Interestingly, the 2 probe sets that 
reliably detect RPL5 ranked on the 8th and 387th position when listing the genes by 
significance (adjusted p-values 0.014 and 0.112) (Supplementary table 6). EVI5 was not 
present in this list of significant probe sets. The top 20 of differentially expressed probe sets 
seemed enriched for genes involved in translation (RPS7, RPL5, RPS21, EIF3M, RPS29 and 
EIF3H) (Table 2). In agreement with this and with previous results18, GSEA revealed the 
ribosome as top downregulated KEGG pathway in bortezomib responders versus non-
responders (Figure 4B, Supplementary table 7). Downregulation of the other ribosomal and 
translation associated genes besides RPL5 in our top 20 did not seem to be caused by 1p22 
deletion associated downregulation of RPL5, because these genes did not differ in 
expression level between 1p22 deleted and non-deleted cases (Supplementary figure 4). 
However, expression of RPL5 did correlate with expression of each of these other genes 
(Supplementary figure 5), suggesting that other mechanisms besides 1p22 deletion are 
regulating expression of this entire ribosome – translation gene set in MM.
Based on Cox regression analysis, only RPL5 expression was significantly associated with 
both PFS and OS (Supplementary figure 6A). We also ran GSEA comparing the genes 
differentially expressed between bortezomib responders and non-responders versus gene sets 
corresponding to each chromosome cytoband. Besides 1p22, region 14q was the only other 
one in the list showing recurrent deletions in MM (Supplementary Table 8). On 1p22, four 
additional genes besides RPL5 were in the list of differentially expressed genes in 
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bortezomib responders, but none ranked as high as RPL5 (SH3GLB1: position 841 in ranked 
list, LRRC8S: 157th, DR1: 342th and 643th and ZNF644: 756th) (Supplementary Table 6). 
These results suggest that although some other genes on 1p22 correlate with bortezomib 
response, expression of RPL5 is the best singular predictor. This is probably due to 
additional effects regulating the expression of RPL5 in MM patients, possibly regulating a 
set of ribosomal/translational genes as a whole. As such, in relation to bortezomib response, 
RPL5 expression acts as a biomarker independent of 1p22 deletion. ROC analysis was 
performed to find an optimal cutoff to predict Bortezomib response (Supplementary figure 
7).
RPL5 expression levels are associated with the survival benefit of bortezomib
The association between RPL5 expression levels and clinical bortezomib response raised the 
question whether RPL5 levels also influence the survival benefit of bortezomib treatment. To 
address this question, we divided the patients from the HOVON-65 trial in two groups 
according to RPL5 expression levels below or above median, and compared survival in the 
bortezomib versus non-bortezomib arm in this trial. PFS of patients with low RPL5 
expression was significantly raised when they were treated on the bortezomib arm to the 
point that their PFS did not differ significantly anymore with PFS of RPL5 high patients 
(median PFS bortezomib protocol 30 months versus 19 months for non-bortezomib, p=0.03; 
Figure 5A, left). On the other hand PFS of RPL5 high patients was not influenced by 
bortezomib (median PFS 34 months versus 33 months, p=0.94; Figure 5A, right). These 
findings were confirmed on the PFS data from the APEX trial (Figure 5B). We performed 
the same analyses for EVI5, but low levels of this gene did not significantly correlate with 
better PFS upon bortezomib treatment (Supplementary figure 8). Cox regression analysis 
was also performed on the other ribosome/translation components found in the GSEA 
analysis. Besides low RPL5 expression, only low RPS7 expression correlated with improved 
PFS on bortezomib treatment in the HOVON-65 and APEX trials (Supplementary figure 6B-
C).
Discussion
Cytoband 1p22 is deleted in ≥20% of MM patients, although no tumor suppressors have 
been identified. Previously, an MDR encompassing 35 genes was defined with MTF2 and 
TMED5 proposed as candidate tumor suppressors. However, no mutations were found in 
these genes, low MTF2 expression does not affect survival, and the association between low 
TMED5 expression and shorter survival is only borderline significant.11,12
We studied a cohort of 35 advanced MM patients and found that 40% of them carried a 1p22 
deletion with two patients having a focal deletion in the region. As such, we delineated a 58 
kb MDR on 1p22.1 in our cohort encompassing only two genes: EVI5 and RPL5. 
Interestingly, the genes in our MDR are also part of the most commonly deleted region on 
1p22 in the public MMRC cohort (Supplementary figure 9). The lower resolution of the 
arrays used to analyze the MMRC cohort may however prohibit detection of smaller lesions 
affecting these genes. It is also worth noting that EVI5 and RPL5 are still part of the MRD 
in our cohort when removing the two cases with highly focal lesions (MM02 and MM05) 
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from our analysis, supporting that our MRD is not purely determined by only these two 
cases. Although mutations in EVI5 and RPL5 are rare, they are the genes in the region with 
the highest frequency of mutations which are predicted to impair protein function. 
Additionally, as discussed below, we do find low expression of EVI5 and RPL5 to be 
correlated with lower PFS and OS.
Data on a potential role of EVI5 in cancer are scarce and support both tumor suppression 
and oncogenic functions.14,22–26 Data linking RPL5 to cancer are piling up and 
consistently support a tumor suppressor role. First, congenital inactivating mutations and 
deletions in RPL5 occur in Diamond Blackfan anemia, a rare bone marrow failure syndrome 
with elevated cancer risks.27,28 Also, inactivating mutations in RPL5 were recently 
described in T-ALL and glioblastoma29,30 and RPL5 is the only gene on 1p22 that was 
identified as recurrently mutated in the pan-cancer project.30–32
It is intriguing that RPL5 and EVI5 deletions are much more common than mutations. This 
may indicate that inactivation of both genes together is required to drive MM progression. 
On the other hand, the plot of RPL5 mRNA expression in 1p22 deleted versus non-deleted 
cases (Figure 2B) indicates that there are cases in which deletion status is a bad predictor of 
RPL5 expression level, suggesting that other mechanisms besides 1p22 deletion can 
downregulate RPL5 expression in MM.
In the second part of this study, we looked into the clinical relevance of RPL5 and EVI5 
expression levels in MM. First of all, we observed a worse PFS and OS in cases with low 
RPL5 and EVI5 mRNA levels in the phase III HOVON-65/ GMMG-HD4 trial on newly 
diagnosed patients, but not in the APEX trial on relapsed patients. These data are in line with 
the known poor prognosis associated with 1p22 deletion at diagnosis.13 As far as we are 
aware, no data are available on the prognostic value of 1p22 lesions in relapse.
Secondly, we found an association between low RPL5 mRNA levels and initial response to 
bortezomib in relapse patients. Due to the lack of copy number data of the patients in the 
HOVON-65 and APEX trials, we could not test association between 1p22 deletion and 
bortezomib response. Our GSEA analysis for chromosomal regions enriched in the signature 
of responders did identify cytoband 1p22, but this enrichment was not as convincing as the 
enrichment we saw for downregulation of ribosome components. These results again 
indicate that the expression of ribosomal proteins is downregulated by additional 
mechanisms other than 1p22 deletion, which may make expression levels of ribosomal 
proteins and RPL5 in particular, more reliable to stratify patients for bortezomib response 
than 1p22 deletion. Although RPL5 expression may be useful to predict response to 
bortezomib in relapse patients, validation in an independent dataset is required. In addition, 
in the relapse patients tested, RPL5 levels were not perfectly associated with response, 
suggesting that adding as yet unknown markers may achieve this.
Thirdly, survival analysis showed that in addition to initial response, low RPL5 expression is 
also correlated with significantly longer PFS for patients treated with bortezomib both upon 
diagnosis and after relapse. Unfortunately, we were unable to analyze OS data because of 
cross-over of patients with progressive disease to an alternative treatment in both trials.16
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Although the introduction of bortezomib has greatly improved prognosis of MM, it has been 
shown before that outcomes vary significantly among patient groups.8, 33 Therefore, 
Terragna et al. recently aimed to molecularly characterize complete response (CR) to 
bortezomib in diagnostic MM. In line with our results, they found loss of a region on 1p22 
to be the CNV most significantly associated with CR after bortezomib treatment.34 
Interestingly, the 660 kb region identified by them includes EVI5 but not RPL5. However, 
the size of RPL5 and the resolution of their copy number arrays may prevent proper 
delineation of the boundary of the deleted area, as we also needed to perform MLPA and 
FISH to confirm that RPL5 was included in one of our focal deletions. Additionally, they list 
another overlapping region on 1p22 as significantly associated with CR that does include 
RPL5. Terragna and colleagues did not find RPL5 to be significantly downregulated on 
mRNA level in CR cases. We suspect however that this could be because of the limited 
number of patients they analyzed. We also only see a slight reduction in the MMRC cohort 
which might escape statistical cutoff in smaller cohorts.
Previously, mutations in NRAS have been associated with lower response rates to single-
agent bortezomib treatment35 while high tight junction protein 1 (TJP1) mRNA expression 
has been linked to a greater likelihood of responding to bortezomib.36,37 Indeed, both 
NRAS and TJP1 are ranked highly in our list of genes differentially expressed between 
responders and non-responders (Supplementary table 6). Additionally, proteomics profiling 
on diagnostic MM patient cells revealed that responders of bortezomib based protocols are 
characterized by altered expression of EIF2 signaling and by extension in refractory patients 
by altered expression of a subset of ribosomal proteins.38
In conclusion, our genetic analyses narrow down the MDR on 1p22 to two genes: EVI5 and 
RPL5, although the exact role of these genes in promoting MM progression remains to be 
determined. Survival analysis shows EVI5 and RPL5 expression are associated with worse 
survival in newly diagnosed patients. In addition, low RPL5 expression levels are linked to 
initial bortezomib response in relapse patients and to survival benefit on bortezomib 
treatment for both diagnostic and relapse patients, leading to a complete recovery of the bad 
prognosis of low RPL5 levels. We thus identify RPL5 mRNA expression as a novel 
biomarker correlating with benefit from bortezomib treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
IH is recipient of an IWT strategisch basisonderzoek PhD fellowship. PVDB is FWO senior clinical investigator. 
This research was funded by an ERC starting grant (n°334946), FWO funding (G067015N and G084013N) and a 
Stichting Tegen Kanker grant (grant n° 2012-176) to KDK. We like to thank Rowan Kuiper for bio-informatic 
advice.
References
1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival 
in multiple myeloma and the impact of novel therapies. Blood. 2008; 111:2516–2520. [PubMed: 
17975015] 
Hofman et al. Page 9
Leukemia. Author manuscript; available in PMC 2017 August 08.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
2. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011; 8:479–491. [PubMed: 
21522124] 
3. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant 
precursor. J Clin Invest. 2012; 122:3456–3463. [PubMed: 23023717] 
4. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. 
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 
2014; 5:2997. [PubMed: 24429703] 
5. Davies FE, Morgan GJ, Walker BA, Boyle EM, Wardell CP, Murison A, et al. Mutational spectrum, 
copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed 
myeloma. J Clin Oncol. 2015; 33:3911–3920. [PubMed: 26282654] 
6. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread 
Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. Cancer Cell. 2014; 
25:91–101. [PubMed: 24434212] 
7. Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, et al. APOBEC family 
mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat 
Commun. 2015; 6:6997. [PubMed: 25904160] 
8. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nature Reviews 
Cancer. 2012; 12:335–348. [PubMed: 22495321] 
9. Corre J, Munshi N, Avet-Loiseau H. Genetics of multiple myeloma: another heterogeneity level? 
Blood. 2015; 125:1870–1876. [PubMed: 25628468] 
10. López-Corral L, Sarasquete ME, Beà S, García-Sanz R, Mateos MV, Corchete LA, et al. SNP-
based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS 
to myeloma status. Leukemia. 2012; 26:2521–9. [PubMed: 22565645] 
11. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of 
myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 
2010; 116:e56–e65. [PubMed: 20616218] 
12. Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, et al. Mapping of 
Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as 
Being Genes in Regions Associated with Adverse Survival. Clin Cancer Res. 2011; 17:7776–7784. 
[PubMed: 21994415] 
13. Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, et al. Deletion of the 1p32 
region is a major independent prognostic factor in young patients with myeloma: the IFM 
experience on 1195 patients. Leukemia. 2013; 28:675–679. [PubMed: 23892719] 
14. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene 
expression model of high-risk multiple myeloma is defined by deregulated expression of genes 
mapping to chromosome 1. Blood. 2006; 109:2276–84. [PubMed: 17105813] 
15. Put N, Lemmens H, Wlodarska I, Konings P, Moreau Y, Hagemeijer A, et al. Interphase 
fluorescence in situ hybridization on selected plasma cells is superior in the detection of 
cytogenetic aberrations in plasma cell dyscrasia. Genes Chromosomes Cancer. 2010; 49 
991-7-997. 
16. Sonneveld P, Schmidt-Wolf IGH, van der Holt B, Jarari el L, Bertsch U, Salwender H, et al. 
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple 
Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. J Clin Oncol. 
2012; 30:2946–2955. [PubMed: 22802322] 
17. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib 
or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352:2487–98. 
[PubMed: 15958804] 
18. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling 
and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 
2006; 109:3177–88. [PubMed: 17185464] 
19. Ritchie ME, Phipson B, Di Wu, Hu Y, Law CW, Shi W, et al. limma powers differential expression 
analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43:e47–e47. 
[PubMed: 25605792] 
Hofman et al. Page 10
Leukemia. Author manuscript; available in PMC 2017 August 08.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set 
enrichment analysis: a knowledge-based approach for interpreting genome-wide expression 
profiles. Proc Natl Acad Sci USA. 2005; 102:15545-50-15550. [PubMed: 16199517] 
21. Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1α-
responsive genes involved in oxidative phosphorylation are coordinately downregulated in human 
diabetes. Nat Genet. 2003; 34:267–273. [PubMed: 12808457] 
22. Samur MK, Shah PK, Wang X, Minvielle S, Magrangeas F, Avet-Loiseau H, et al. The shaping and 
functional consequences of the dosage effect landscape in multiple myeloma. BMC Genomics. 
2013; 14:672. [PubMed: 24088394] 
23. Liao X, Buchberg AM, Jenkins NA, Copeland NG. Evi-5, a common site of retroviral integration 
in AKXD T-cell lymphomas, maps near Gfi-1 on mouse chromosome 5. J Virol. 1995; 69:7132–7. 
[PubMed: 7474133] 
24. Li Y, Xu D, Bao C, Zhang Y, Chen Di, Zhao F, et al. MicroRNA-135b, a HSF1 target, promotes 
tumor invasion and metastasis by regulating RECK and EVI5 in hepatocellular carcinoma. 
Oncotarget. 2014; 6:2421–33.
25. Baron BW, Anastasi J, Bies J, Reddy PL. GFI1B, EVI5, MYB—Additional genes that cooperate 
with the human BCL6 gene to promote the development of lymphomas. Blood Cells. 2014; 52:68–
75.
26. Jacob B, Osato M, Yamashita N, Wang CQ, Taniuchi I, Littman DR, et al. Stem cell exhaustion due 
to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis. Blood. 2010; 115:1610–
1620. [PubMed: 20008790] 
27. Gazda HT, Sheen MR, Vlachos A, Choesmel V, O'Donohue M-F, Schneider H, et al. Ribosomal 
protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-
Blackfan anemia patients. Am J Hum Genet. 2008; 83:769–80. [PubMed: 19061985] 
28. Vlachos A, Rosenberg PS, Atsidaftos E, Alter BP, Lipton JM. Incidence of neoplasia in Diamond 
Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood. 2012; 119:3815–
3819. [PubMed: 22362038] 
29. De Keersmaecker K, Atak ZK, Li N, Vicente C, Patchett S, Girardi T, et al. Exome sequencing 
identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic 
leukemia. Nat Genet. 2013; 45:186–190. [PubMed: 23263491] 
30. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery 
and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505:495–501. 
[PubMed: 24390350] 
31. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, Reimand J, et al. 
Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 
2013; 3:2650. [PubMed: 24084849] 
32. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and 
significance across 12 major cancer types. Nature. 2013; 502:333–339. [PubMed: 24132290] 
33. Corre J, Avet-Loiseau H. The impact of genomics on the management of myeloma. J Natl Compr 
Canc Netw. 2011; 9:1200–6. [PubMed: 21975916] 
34. Terragna C, Remondini D, Martello M, Zamagni E, Pantani L, Patriarca F, et al. The genetic and 
genomic background of multiple myeloma patients achieving complete response after induction 
therapy with bortezomib, thalidomide and dexamethasone (VTD). Oncotarget. 2016; 7:9666–9679. 
[PubMed: 26575327] 
35. Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, et al. Mutation of NRAS 
but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. 
Blood. 2013; 123:632–9. [PubMed: 24335104] 
36. Zhang X-D, Baladandayuthapani V, Lin HY, Barlogie B, Usmani SZ, Yang L, et al. Identification 
Of Tight Junction Protein (TJP)-1 As a Modulator and Biomarker Of Proteasome Inhibitor 
Sensitivity In Multiple Myeloma. Blood. 2013; 122:123.
37. Zhang X-D, Baladandayuthapani V, Lin H, Mulligan G, Bin Li, Esseltine D-LW, et al. Tight 
Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in 
Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell. 2016; 29:639. [PubMed: 
27132469] 
Hofman et al. Page 11
Leukemia. Author manuscript; available in PMC 2017 August 08.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
38. Dytfeld D, Rosebeck S, Kandarpa M, Mayampurath A, Mellacheruvu D, Alonge MM, et al. 
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated 
with favourable response to bortezomib-based treatment regimens. Br J Haematol. 2015; 170:66–
79. [PubMed: 25824111] 
Hofman et al. Page 12
Leukemia. Author manuscript; available in PMC 2017 August 08.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1. Genetic analysis of chromosomal region 1p22 reveals RPL5 and EVI5 as candidate 
tumor suppressors
(A) Ideogram of chromosome 1 with indication of the size of the 1p22 deletions detected in 
this study. (B) Average weighted log2 array ratio of 1p22 genes. Each dot in the graph 
represents a gene on 1p22, and genes are represented from telomeric (left, 85 Mbp) to 
centromeric (right, 95 Mbp). The region that shows the lowest average weighted log2 array 
ratio defining the MDR in our cohort is indicated in red and gene names are shown. (C) 
Focal 1p22.1 deletions in cases MM05 and MM02. Deleted areas are indicated by the grey 
shaded areas, the dark grey shaded area shows the overlapping deleted region (MDR). (D) 
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FISH with probes RP11-1E09 and RP11-456E23 on bone marrow of patients MM05 and 
MM02. Schematic representation of the genomic region targeted by the FISH probes is 
shown in panel C. Note loss of one RP11-1E09 (green) signal in MM02 and loss of one 
RP11-456E23 (green) signal in MM05. The latter case displayed both RP11-1E09 (red) 
signals, because the BAC covers a larger region than the deleted sequences in MM05. (E) 
MLPA assay confirming deletion of exon 1-4 of the RPL5 gene in case MM02. The assay 
measures copy number of exons of several ribosomal protein genes. Peaks representing 
signals that correspond to exons of RPL5 are indicated, with deleted exons in red and non-
deleted exons in black.
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Figure 2. EVI5 and RPL5 show the highest incidence of mutations predicted to impair protein 
function and their expression levels correlate with 1p22 deletion status
(A) Mutation score for all 1p22.1 genes. Mutation score per gene was calculated by taking 
the mutation count for each gene and by correcting this value for gene length and predicted 
functional impact of the mutations. The MDR identified in Figure 1B is again indicated in 
red. (B) Gene expression plots of EVI5 (probe set 209717_s_at) and RPL5 (200937_s_at) in 
1p22 wt versus deleted cases. The red horizontal lines indicate the average value in the 
group and the standard deviations. p-values were calculated using a 2-tailed Mann-Whitney 
test. The fold change below the plot indicates the fold downregulation in 1p22 deleted cases.
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Figure 3. Low EVI5 and RPL5 expression correlates with shorter PFS and OS in newly 
diagnosed but not in relapse patients
(A) Kaplan-Meier curves comparing PFS (left) and OS (right) of RPL5 low and high 
expressing cases in the phase III HOVON-65/ GMMG-HD4 trial. (B) PFS and OS of EVI5 
low and high expressing cases in the phase III HOVON-65/ GMMG-HD4 trial. ‘Low’ and 
‘high’ are defined here as expression below and above median. p-values were calculated 
with Log-rank tests.
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Figure 4. Reduced expression of RPL5 and other ribosomal proteins correlates with response to 
bortezomib
(A) Gene expression plots of RPL5 (probe set 200937_s_at) in bortezomib responders and 
non-responders in the APEX trial. The red horizontal lines indicate the average value in the 
group and the standard deviations. P-values were calculated using a 2-tailed Mann-Whitney 
test. The fold change indicates the fold downregulation in responders. (B) GSEA plot 
supporting downregulation of the genes in KEGG pathway ‘ribosome’ in bortezomib 
responders.
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Figure 5. RPL5 expression levels are associated with the benefit of bortezomib on PFS
(A) Kaplan-Meier curves comparing PFS of RPL5 low (left) and high (right) expressing 
patients for bortezomib versus non-bortezomib arms in the HOVON-65/ GMMG-HD4 trial. 
(C) Kaplan-Meier curves comparing PFS of RPL5 low (left) and high (right) expressing 
patients for bortezomib versus dexamethasone arms in the APEX trial. Low and high 
expression are defined here as below and above median. All p-values were calculated with 
Log-rank tests.
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Table 1
Cox regression values
Cox regression analysis of OS and PFS (Figure 3)
PFS OS
Exp (B) 95% CI p HR 95% CI p
HOVON-65/GMMG-HD4
RPL5 0.81 0.70-0.93 0.003 0.78 0.65-0.93 0.006
EVI5 0.89 0.79-1.01 0.072 0.78 0.65-0.93 0.006
APEX
RPL5 1 0.85-1.14 0.848 1.03 0.89-1.21 0.677
EVI5 0.98 0.85-1.12 0.731 0.89 0.76-1.04 0.149
Cox regression analysis on PFS in RPL5 low versus high expressing cases for bortezomib versus control treatment (Figure 5)
PFS
Exp (B) 95% CI p
HOVON-65/GMMG-HD4
RPL5 low: Bz vs. CTRL 0.67 0.47-0.96 0.03
RPL5 high: Bz vs. CTRL 0.99 0.69-1.41 0.9
APEX
RPL5 low: Bz vs. CTRL 0.57 0.37-0.89 0.01
RPL5 high: Bz vs. CTRL 0.95 0.59-1.51 0.8
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Table 2
Top 20 of probe sets with differential signal in bortezomib responders versus non-
responders in the APEX trial
Probe Gene log2FC P adj.
210532_s_at C14orf2 -0.408 0.002
225335_at ZNF496 -0.540 0.002
217988_at CCNB1IP1 -0.590 0.002
229586_at CHD9 0.424 0.008
224985_at NRAS -0.470 0.008
224616_at DYNC1LI2 0.459 0.014
213941_x_at RPS7 -0.340 0.014
200937_s_at RPL5 ; SNORD21 -0.553 0.014
206790_s_at NDUFB1 -0.388 0.019
200834_s_at RPS21 -0.431 0.019
202232_s_at EIF3M -0.521 0.019
224841_x_at GAS5 ; SNORD44 ; SNORD47 ; SNORD74 ; SNORD76 ; SNORD77 ; SNORD79 ; SNORD80 ; 
SNORD81
-0.854 0.019
224741_x_at GAS5 ; SNORD44 ; SNORD47 ; SNORD74 ; SNORD76 ; SNORD77 ; SNORD79 ; SNORD80 ; 
SNORD81
-0.879 0.019
221180_at MAP3K19 0.580 0.019
208752_x_at NAP1L1 -0.406 0.019
213846_at COX7C -0.394 0.019
238025_at MLKL 0.607 0.019
200921_s_at BTG1 -0.666 0.019
201094_at RPS29 -0.419 0.019
201592_at EIF3H -0.383 0.020
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